Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Francois, Gonzalvez"'
Autor:
Andreas Jekle, Santosh Kumar Thatikonda, Ruchika Jaisinghani, Suping Ren, April Kinkade, Sarah K. Stevens, Antitsa Stoycheva, Vivek K. Rajwanshi, Caroline Williams, Jerome Deval, Sucheta Mukherjee, Qingling Zhang, Sushmita Chanda, David B. Smith, Lawrence M. Blatt, Julian A. Symons, Francois Gonzalvez, Leonid Beigelman
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 22, p 16274 (2023)
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking the innate and acquired immune systems.
Externí odkaz:
https://doaj.org/article/512c73ca5afc43cb8be9c4e5e591a5b8
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non–small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR-mutated NSCLC, moboc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1233d4a09c246c7e577a052bb61a6464
https://doi.org/10.1158/2159-8290.c.6549370.v1
https://doi.org/10.1158/2159-8290.c.6549370.v1
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Supplementary Tables (S1-6) and Figures (S1-6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b1686b17282cc4afaa22ed044b1306
https://doi.org/10.1158/2159-8290.22540399
https://doi.org/10.1158/2159-8290.22540399
Autor:
Kwok-Kin Wong, Sylvie Vincent, Rachael Brake, Victor M. Rivera, Haiquan Chen, Francois Gonzalvez, Sittinon Tang, Eleni Papadopoulos, Cassandra Thakurdin, Val Pyon, Hai Hu, Hailin Ding, Yuanwang Pan, Hua Zhang, Fei Li, Theresa E. Baker, Zhendong Gao, Jiehui Deng, David Peng, Jiansheng Wu, Johara Chouitar, Shougen Cao, Kwan Ho Tang, Chengwei Peng, Shengwu Liu, Michael Fitzgerald, Ting Chen, Shuai Li, Han Han
GSEA analysis of mobocertinib and T-DM1 treated tumors versus mobocertinib-only treated tumors Genes involved in "INTERFERON ALPHA RESPONSE", "INFLAMMATORY RESPONSE", "INTERFERON GAMMA RESPONSE", "IL2 STAT5 SIGNALING", "TNFA SIGNALING VIA NFKB" and "
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc292ba115983e2e9d41bf0078c4067
https://doi.org/10.1158/0008-5472.22490195
https://doi.org/10.1158/0008-5472.22490195
Autor:
Kwok-Kin Wong, Sylvie Vincent, Rachael Brake, Victor M. Rivera, Haiquan Chen, Francois Gonzalvez, Sittinon Tang, Eleni Papadopoulos, Cassandra Thakurdin, Val Pyon, Hai Hu, Hailin Ding, Yuanwang Pan, Hua Zhang, Fei Li, Theresa E. Baker, Zhendong Gao, Jiehui Deng, David Peng, Jiansheng Wu, Johara Chouitar, Shougen Cao, Kwan Ho Tang, Chengwei Peng, Shengwu Liu, Michael Fitzgerald, Ting Chen, Shuai Li, Han Han
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3282ae56d3b65e02abbca4ecf45fe434
https://doi.org/10.1158/0008-5472.c.6533114
https://doi.org/10.1158/0008-5472.c.6533114
Autor:
Kwok-Kin Wong, Sylvie Vincent, Rachael Brake, Victor M. Rivera, Haiquan Chen, Francois Gonzalvez, Sittinon Tang, Eleni Papadopoulos, Cassandra Thakurdin, Val Pyon, Hai Hu, Hailin Ding, Yuanwang Pan, Hua Zhang, Fei Li, Theresa E. Baker, Zhendong Gao, Jiehui Deng, David Peng, Jiansheng Wu, Johara Chouitar, Shougen Cao, Kwan Ho Tang, Chengwei Peng, Shengwu Liu, Michael Fitzgerald, Ting Chen, Shuai Li, Han Han
Figure S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b801af9cd01bb649be8ad1b6d441cd
https://doi.org/10.1158/0008-5472.22490216
https://doi.org/10.1158/0008-5472.22490216
Autor:
Hua Zhang, Haiquan Chen, Sittinon Tang, Shougen Cao, Yuanwang Pan, Victor M. Rivera, Shuai Li, Fei Li, Kwan Ho Tang, Hai Hu, Chengwei Peng, Francois Gonzalvez, Hailin Ding, Jiehui Deng, Johara Chouitar, Han Han, Sylvie Vincent, Theresa E. Baker, Michael Fitzgerald, Val Pyon, Ting Chen, Zhendong Gao, Rachael L. Brake, Eleni Papadopoulos, David H. Peng, Jiansheng Wu, Cassandra Thakurdin, Kwok-Kin Wong, Shengwu Liu
Publikováno v:
Cancer Research. 81:5311-5324
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor
Autor:
Wei-Sheng, Huang, Feng, Li, Yongjin, Gong, Yun, Zhang, Willmen, Youngsaye, Yongjin, Xu, Xiaotian, Zhu, Matthew T, Greenfield, Anna, Kohlmann, Paul M, Taslimi, Angela, Toms, Stephan G, Zech, Tianjun, Zhou, Biplab, Das, Hyun G, Jang, Meera, Tugnait, Yihua E, Ye, Francois, Gonzalvez, Theresa E, Baker, Sara, Nadworny, Yaoyu, Ning, Scott D, Wardwell, Sen, Zhang, Alexandra E, Gould, Yongbo, Hu, Weston, Lane, Robert J, Skene, Hua, Zou, Tim, Clackson, Narayana I, Narasimhan, Victor M, Rivera, David C, Dalgarno, William C, Shakespeare
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 80:129084
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this subset of mutants is generally resistant to mo
Autor:
Tongfei Wu, Sarah Stevens, Cheng Liu, Kristina Rekstyte-Matiene, Elke Behaeghel, Sucheta Mukherjee, Sandra Chang, Ruchika Jaisinghani, Antitsa Stoycheva, Andreas Jekle, Qingling Zhang, Kusum Gupta, Jerome Deval, Julian Symons, Lawrence Blatt, Leonid Beigelman, Pierre Raboisson, Francois Gonzalvez
Publikováno v:
Journal of Hepatology. 77:S853
Autor:
Han, Han, Shuai, Li, Ting, Chen, Michael, Fitzgerald, Shengwu, Liu, Chengwei, Peng, Kwan Ho, Tang, Shougen, Cao, Johara, Chouitar, Jiansheng, Wu, David, Peng, Jiehui, Deng, Zhendong, Gao, Theresa E, Baker, Fei, Li, Hua, Zhang, Yuanwang, Pan, Hailin, Ding, Hai, Hu, Val, Pyon, Cassandra, Thakurdin, Eleni, Papadopoulos, Sittinon, Tang, Francois, Gonzalvez, Haiquan, Chen, Victor M, Rivera, Rachael, Brake, Sylvie, Vincent, Kwok-Kin, Wong
Publikováno v:
Cancer Res
No targeted treatments are currently approved for HER2 exon 20 insertion-mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor 2